Literature DB >> 18486259

Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways.

Olav A Gressner1, Birgit Lahme, Katharina Rehbein, Monika Siluschek, Ralf Weiskirchen, Axel M Gressner.   

Abstract

BACKGROUND/AIMS: Epidemiological studies suggest that coffee drinking is inversely correlated with the risk of development of liver fibrosis but the molecular basis is unknown.
METHODS: We investigated the pharmacological mechanisms involved in caffeine-dependent regulation of CTGF expression, an important modulator protein of fibrogenic TGF-beta, in rat hepatocytes using Western-blot, co-immunoprecipitations, reporter-gene-assays and ELISAs.
RESULTS: It is demonstrated that caffeine, similar to 8-Br-cAMP, suppresses CTGF expression, decreases SMAD2 protein levels and inhibits SMAD1/3-phosphorylation. The SMAD2 level can be restored by a proteasome inhibitor. Additionally, caffeine leads to an up-regulation of PPARgamma expression, that enhances the inhibitory effect of the natural PPARgamma agonist 15-PGJ(2) on CTGF expression by inducing a dissociation of the SMAD2/3-CBP/p300-transcriptional complex.
CONCLUSIONS: We show that caffeine strongly down-modulates TGF-beta-induced CTGF expression in hepatocytes by stimulation of degradation of the TGF-beta effector SMAD 2, inhibition of SMAD3 phosphorylation and up-regulation of the PPARgamma-receptor. Long-term caffeinization might be an option for anti-fibrotic trials in chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486259     DOI: 10.1016/j.jhep.2008.03.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

1.  The Starbuck stops here: it's a Smad world.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2008-07-23       Impact factor: 5.782

2.  Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes.

Authors:  Zhenyue Tong; Ruju Chen; Daniel S Alt; Sherri Kemper; Bernard Perbal; David R Brigstock
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

3.  Coffee: a panacea or snake oil for the liver?

Authors:  Radhika Kumari; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Coffee and liver - long way to go.

Authors:  Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

5.  Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation.

Authors:  Wen-Xing Ding
Journal:  Hepatology       Date:  2014-02-14       Impact factor: 17.425

6.  Coffee prevents CCl(4)-induced liver cirrhosis in the rat.

Authors:  Mario G Moreno; Enrique Chávez; Liseth R Aldaba-Muruato; José Segovia; Paula Vergara; Víctor Tsutsumi; Mineko Shibayama; Yadira Rivera-Espinoza; Pablo Muriel
Journal:  Hepatol Int       Date:  2011-01-25       Impact factor: 6.047

7.  Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.

Authors:  Anita Pathil; Jan Mueller; Johannes M Ludwig; Jiliang Wang; Arne Warth; Walee Chamulitrat; Wolfgang Stremmel
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

8.  PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.

Authors:  Jun Wei; Asish K Ghosh; Jennifer L Sargent; Kazuhiro Komura; Minghua Wu; Qi-Quan Huang; Manu Jain; Michael L Whitfield; Carol Feghali-Bostwick; John Varga
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

9.  Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.

Authors:  Asish K Ghosh; Swati Bhattacharyya; Jun Wei; Suyeon Kim; Yaacov Barak; Yasuji Mori; John Varga
Journal:  FASEB J       Date:  2009-04-24       Impact factor: 5.191

10.  Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?

Authors:  Andrew Leask; Sunil K Parapuram; Xu Shi-Wen; D J Abraham
Journal:  J Cell Commun Signal       Date:  2009-01-21       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.